Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer (NCT04725994)

🧪 Interventions in This Study

• IDX-1197+XELOX (DRUG)
• IDX-1197+Irinotecan (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (17 Sites)

• USC Norris Comp. Cancer Ctr Hospital — Los Angeles, California
• Hematology Oncology Clinic Baton Rouge / Sarah Cannon — Baton Rouge, Louisiana
• Beth Israel Deaconess Medical Center — Boston, Massachusetts
• Dana Farber Cancer Institute — Boston, Massachusetts
• Astera Cancer Care — East Brunswick, New Jersey
• Beijing Cancer Hospital — Beijing,
• The Sixth Affiliated Hospital of Sun Yat-Sen University — Guangzhou,
• Shanghai East Hospital — Shanghai,
• Jeonbuk National University Hospital — Jeonju, Jeollabuk-do
• Dong-A University Hospital — Busan,
• Seoul National University Bundang Hospital — Seongnam,
• Korea University Anam Hospital — Seoul,
• Korea University Guro Hospital — Seoul,
• Asan Medical Center — Seoul,
• Samsung Medical Center — Seoul,
• Seoul National University Hospital — Seoul,
• Severance Hospital - Yonsei Cancer Center — Seoul,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Gastric Cancer

• A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors — Scottsdale, Arizona
• Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) — Baltimore, Maryland
• Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer — Baltimore, Maryland
• Study for AZD4360 in Participants With Advanced Solid Tumours — Santa Monica, California
• Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma — Tampa, Florida

Explore by condition: All Gastric Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.